CN115175912B - N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 - Google Patents

N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 Download PDF

Info

Publication number
CN115175912B
CN115175912B CN202080082800.6A CN202080082800A CN115175912B CN 115175912 B CN115175912 B CN 115175912B CN 202080082800 A CN202080082800 A CN 202080082800A CN 115175912 B CN115175912 B CN 115175912B
Authority
CN
China
Prior art keywords
compound
crystalline form
present disclosure
hormone
xiii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080082800.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115175912A (zh
Inventor
C·雅古施
C·K·赫兹
A·施罗德
P·I·弗拉霍瓦
S·斯蒂威斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Myovant Sciences GmbH
Sumitomo Pharma Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences GmbH, Sumitomo Pharma Switzerland GmbH filed Critical Myovant Sciences GmbH
Publication of CN115175912A publication Critical patent/CN115175912A/zh
Application granted granted Critical
Publication of CN115175912B publication Critical patent/CN115175912B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080082800.6A 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 Active CN115175912B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913606P 2019-10-10 2019-10-10
US62/913,606 2019-10-10
PCT/EP2020/078475 WO2021069700A1 (en) 2019-10-10 2020-10-09 Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Publications (2)

Publication Number Publication Date
CN115175912A CN115175912A (zh) 2022-10-11
CN115175912B true CN115175912B (zh) 2025-04-11

Family

ID=72852647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080082800.6A Active CN115175912B (zh) 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式

Country Status (5)

Country Link
US (1) US12655154B2 (enExample)
EP (1) EP4041738A1 (enExample)
JP (1) JP7713934B2 (enExample)
CN (1) CN115175912B (enExample)
WO (1) WO2021069700A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947734A (zh) * 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (enExample) 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (ja) 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JPH10298156A (ja) 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
JP2001316391A (ja) 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
GB2361917A (en) 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002088044A (ja) 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
DE60207280T2 (de) 2001-09-04 2006-05-18 Akzo Nobel N.V. GLYCINSUBSTITUIERTE THIENO[2,3-d]PYRIMIDINE MIT KOMBINIERTER LH- UND FSH-AGONISTISCHER WIRKUNG
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
EP1806053A1 (en) 2004-10-25 2007-07-11 Nihon Nohyaku Co., Ltd. Herbicide compositions for upland farming and control method
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
US20110172249A1 (en) 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
JP2010229098A (ja) 2009-03-27 2010-10-14 Central Glass Co Ltd イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
TWI508962B (zh) * 2009-04-22 2015-11-21 Du Pont 氮雜環醯胺之固體形態
CN103282365B (zh) * 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
JP2017088564A (ja) 2015-11-13 2017-05-25 株式会社トクヤマ ミルタザピンの製造方法
CN108430990B (zh) 2015-12-25 2020-08-25 山东轩竹医药科技有限公司 喹唑啉衍生物的晶体及其制备方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US20170275330A1 (en) 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
SI3518932T1 (sl) 2016-09-30 2025-03-31 Takeda Pharmaceutical Company Limited Zdravljenje raka prostate
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
EP3969455A4 (en) * 2019-05-15 2023-07-05 Dr. Reddy's Laboratories Limited AMORPHOUS AND CRYSTALLINE FORMS OF RELUGOLIX
CA3145993A1 (en) 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112390812A (zh) 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
CN112771052B (zh) 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
CN112552312B (zh) 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN113620972A (zh) 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
WO2023042214A1 (en) 2021-09-15 2023-03-23 Cipla Limited Solid state forms of relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023119333A1 (en) 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
IN202221021078A (enExample) 2022-04-08 2023-10-13
CN115417883B (zh) 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947734A (zh) * 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法

Also Published As

Publication number Publication date
CN115175912A (zh) 2022-10-11
JP2022551525A (ja) 2022-12-09
US12655154B2 (en) 2026-06-16
US20220372044A1 (en) 2022-11-24
JP7713934B2 (ja) 2025-07-28
WO2021069700A1 (en) 2021-04-15
EP4041738A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
JP7713934B2 (ja) Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
US11760756B2 (en) Crystalline form of a PD-1/PD-L1 inhibitor
US9844550B2 (en) Phtalazinone derivatives and manufacturing process thereof
CN115279769A (zh) N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP3227295B1 (en) 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
IL294225B1 (en) Method for preparing a protein disintegrating agent compound and application
TW202012384A (zh) 特定芳基普拉二烯內酯化合物及其使用方法
TW200521133A (en) Novel 17β-hydroxysteroid dehydrogenase type I inhibitors
CN119744262A (zh) 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途
JP2024546478A (ja) Ｒａｆキナーゼ阻害剤及びその使用方法
US20250171421A1 (en) Enantiomerically purified gper agonist for use in treating disease states and conditions
WO2022184103A1 (zh) 三并环化合物及其药物组合物和应用
JP2020536872A (ja) ３−置換１，２，４−オキサジアゾールの結晶形態
TW202444723A (zh) 喜樹鹼衍生物、藥物組合物及其製備方法和用途
CN112979532A (zh) 邻苯二甲酰亚胺类化合物、制备方法和应用
CN114644635B (zh) 三氮唑类三并环衍生物及其制备方法和应用
TW200829572A (en) Crystal modifications
TW202021950A (zh) 作為免疫調節劑的化合物及其製備方法和應用
US20230286900A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
WO2025237404A1 (zh) 一种mc4r拮抗剂的多晶型物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Switzerland

Address after: Basel, SUI

Applicant after: Sumitomo Pharmaceutical Switzerland Ltd.

Address before: Basel, SUI

Applicant before: MYOVANT SCIENCES GmbH

Country or region before: Switzerland

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20260306

Address after: Osaka

Patentee after: SUMITOMO PHARMACEUTICALS CO.,LTD.

Country or region after: Japan

Address before: Basel

Patentee before: Sumitomo Pharmaceutical Switzerland Ltd.

Country or region before: Switzerland